(Q34666391)

3 August 2017

1 reference

title

Targeting epidermal growth factor receptor in lung cancer (English)

1 reference

3 August 2017

1 reference

José Baselga

1

1 reference

3 August 2017

Joan Albanell

series ordinal

2

1 reference

3 August 2017

publication date

1 July 2002

1 reference

3 August 2017

published in

Current Oncology Reports

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

317-324

1 reference

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

3 August 2017

cites work

1 reference

12 December 2020

New therapeutic agents targeting the epidermal growth factor receptor.

1 reference

12 December 2020

The epidermal growth factor receptor as a target for cancer therapy

1 reference

12 December 2020

Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development.

1 reference

12 December 2020

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Regulation of signal transduction and signal diversity by receptor oligomerization

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma

1 reference

12 December 2020

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

1 reference

12 December 2020

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention

1 reference

12 December 2020

CI-1033, a pan-erbB tyrosine kinase inhibitor

1 reference

12 December 2020

Targeting the epidermal growth factor receptor: a clinical reality

1 reference

12 December 2020

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer

1 reference

12 December 2020

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice

1 reference

12 December 2020

10.1007/S11912-002-0007-1

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1017496319

0 references

1 reference